Home   >  
PI3K/Akt/mTOR
  >  
AKT
  >   Ipatasertib dihydrochloride
Ipatasertib dihydrochloride Chemical Structure

Ipatasertib dihydrochloride

Data Sheet For research use only. Not for human use.
Cat. No. :BCP23821CAS No. :1396257-94-5Purity:98%
 Tel: 0086-13026320035   or   orders@biochempartner.com
Real-Time Inquiry ×

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Inquiry Online ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Bulk Inquiry ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

  • Chemical Properties&Biological Activity
CAS No. 1396257-94-5 Cat. No. BCP23821
Name Ipatasertib dihydrochloride
Synonyms GDC0068 2HCl;Ipatasertib 2HCl;GDC0068 dihydrochloride;GDC-0068 dihydrochloride; RG-7440 dihydrochloride;
SMILES CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O.Cl.Cl
Chemical Name
Formula C24H34Cl3N5O2 M. Wt 530.92
Purity 98% Storage Store at 4-8°C
Description Ipatasertib is typically efficacious in xenograft models in which Akt is activated because of genetic alterations including PTEN loss, PIK3CA mutations/amplifications, or HER2 overexpression. In these models, tumor growth delay, stasis, or regression is achieved at or below 100 mg/kg daily oral dose, which is the maximum dose tested in immunocompromised mice that is well tolerated. When tested in vivo, daily dosing of Ipatasertib in combination with Docetaxel induces tumor regression and stasis in the PC-3 and MCF7-neo/HER2 xenograft models, at doses where each single agent is ineffective or only causes modest tumor growth delay. Similarly, increased TGI is observed in the OVCAR3 ovarian cancer xenograft model when Ipatasertib is combined with Carboplatin. The combination of Ipatasertib with Docetaxel or Carboplatin is tolerated with less than 5% body weight loss when compared with treatment with each chemotherapeutic agent alone.
  • Quality Control&Technical Support
In the process of purchasing and using Biochempartner products, you can consult us if you have any problems: orders@biochempartner.com. We will try our best to solve all your doubts.

Recommend Products

More >

Tags:Ipatasertib dihydrochloride supplier,Ipatasertib dihydrochloride purchase,Ipatasertib dihydrochloride manufacturer,Ipatasertib dihydrochloride distributor,Ipatasertib dihydrochloride cost,Ipatasertib dihydrochloride buy,Ipatasertib dihydrochloride for sale

0086-13720134139